MiR-19a regulates PTEN expression to mediate glycogen synthesis in hepatocytes
Citations Over TimeTop 12% of 2015 papers
Abstract
MiR-19a, a member of mir-17-92 microRNA clusters, has been demonstrated to promote cell proliferation and angiogenesis via regulating the PI3K/AKT pathway, the major insulin signaling pathway. However, whether miR-19a plays an important role in glycogen synthesis in hepatocytes remains unknown. Here, we define the impact of miR-19a on glycogen synthesis and IL-6-induced reduced glycogenesis in hepatocytes and its underlying mechanisms. Our studies indicate that miR-19a was down-regulated in the livers of db/db mice and mice injected with IL-6, as well as mouse NCTC 1469 hepatocytes and HEP 1-6 hepatocytes treated by IL-6. We found that over-expression of miR-19a in NCTC 1469 cells and HEP 1-6 cells led to increased activation of the AKT/GSK pathway and synthesis of glycogen, whereas down-regulation of miR-19a impaired AKT/GSK phosphorylation and glycogenesis. Over-expression of miR-19a ameliorated IL-6-induced reduced glycogen synthesis in hepatocytes. Moreover, we identified PTEN as the target of miR-19a by a luciferase assay. Down-regulation of PTEN rescued the effects of miR-19a suppression on the activation of the AKT/GSK pathway and improved glycogenesis in NTC 1469 cells. These findings show for the first time that miR-19a might activate the AKT/GSK pathway and glycogenesis via down-regulation of PTEN expression.
Related Papers
- → Organizing glucose disposal: emerging roles of the glycogen targeting subunits of protein phosphatase-1.(2000)188 cited
- → Substrate cycling between glucose 6-phosphate and glycogen occurs in Schistosoma mansoni(1990)16 cited
- → The Stimulation of Glycogen Synthesis and of Glycogen Synthetase in the Liver by the Administration of Glucose(1967)122 cited
- → Contraction Activates Glycogen Synthase Independently of Initial Glycogen Concentration(2006)
- → Η προβλεπτική αξία των μεταλλάξεων του γονιδίου PI3K και της απώλειας της έκφρασης του γονιδίου PTEN σε ασθενείς με πρώιμο καρκίνο μαστού που έλαβαν συμπληρωματική θεραπεία με τραστουζουμάμπη(2019)